Soligenix reports Q3 EPS (16c) vs ($1.15) last year

Reports Q3 revenue $0.1M vs $0.2M last year. “We continue our collaborative discussions with the U.S. Food and Drug Administration regarding the design of a second, confirmatory Phase 3 pivotal study evaluating HyBryte in the treatment of cutaneous T-cell lymphoma, where we successfully demonstrated statistically significant results in the first Phase 3 clinical trial,” stated Christopher Schaber, PhD, President and Chief Executive Officer of Soligenix. “We continue to actively enroll patients in the Phase 2a trial of SGX302 for the treatment of mild-to-moderate psoriasis after demonstration of a clear biological signal in all five of the initial patients, with the majority recording an improvement in their PASI score. Under our Public Health Solutions business segment, we continue to advance our heat stable vaccine platform technology, ThermoVax. Most recently, we successfully demonstrated two year stability of thermostabilized bivalent and trivalent filovirus vaccine candidates at temperatures of 40 degrees Celsius when formulated in a single vial, needing reconstitution only with sterile water immediately prior to use. This follows the previous successful demonstration of 100% protection of non-human primates against lethal Sudan ebolavirus and Marburg marburgvirus challenge with the bivalent vaccine.”